

Breast Cancer Diagnostic and Drug Technologies: Global Markets

<https://marketpublishers.com/r/B80E6364683EN.html>

Date: November 2019

Pages: 150

Price: US\$ 2,750.00 (Single User License)

ID: B80E6364683EN

Abstracts

REPORT SCOPE:

This report is an update to Breast Cancer Diagnostics and Therapeutics Market Report-HLC106B.

The objective of the current report is to provide readers with updated market estimates for the diagnostics and therapeutics market. This report also highlights current and future market potential for breast cancer therapeutics along with a detailed analysis of the competitive environment, pipeline drugs, blockbuster drugs and other diagnostic and therapeutic developments.

This report includes breast cancer epidemiology including global and regional prevalence, incidence and mortality rates, the regulatory environment for markers and therapeutics, recent regulatory approvals, current and new technologies, market projections and the market share of key market players. Market drivers, trends and potential regional market opportunities for diagnostics and therapeutics are also identified in this report.

This report details currently available diagnostic breast cancer screening tests, breast cancer staging and prognostic technology advancements, predictive diagnostic tests and the latest therapy developments for breast cancer treatment. This study evaluates available tumor marker-based predictive companion tests and FDA-approved drugs that treat breast cancer. Screening biomarkers, pipeline analysis, patent analysis and reimbursement scenarios are some additions to the current report.

This report includes market estimates for breast cancer diagnostics (mammography,

biopsy and companion diagnostics), therapeutics and market share of therapeutics by drug class (HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors and hormone receptors), geographic market segmentation of the overall market and global market share by company with special emphasis on developed and underdeveloped geographic regions. For market estimates, data has been provided for the year 2018 (the base year), 2019 and a forecast for 2024.

REPORT INCLUDES:

26 data tables and 49 additional tables

Brief overview of the global markets for breast cancer therapeutics and drug technologies

Analyses of global market trends with data from 2018, estimates for 2019 and projections of compound annual growth rates (CAGRs) through 2024

Country specific data and analysis for the U.S., Canada, Mexico, Germany, Italy, U.K, France, China, India, Japan, South Korea, Brazil, South Africa and MEA

Revenue details of the global mammography, biopsy, companion diagnostic IVD, and therapeutic markets by various segments and subsegments

Competitive landscape covering key market participants and their market share analysis

Information on merger and acquisition details, partnerships and alliances, product launch strategies, pipeline drugs, blockbuster drugs, and other novel drugs development

A relevant patent analysis

Profile descriptions of the key market leaders, including AbbVie Inc., Abbott Laboratories, Dako, Eli Lilly and Co., Nanostring Technologies, Pfizer Inc., Puma Biotechnology Inc., and Sanofi S.A.

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND

Introduction
Classification of Breast Cancer by Type
Non-invasive Breast Cancers
Invasive Breast Cancer
Molecular Subtypes of Breast Cancer
Luminal A
Luminal B Types
HER2 Type
HER2-Amplified
Triple-Negative Breast Cancer (TNBC) or Basal Type
Normal-Like
Breast Cancer Causes, Indications and Risk Factors
Symptoms
Breast Cancer Staging
Epidemiology
United States Breast Cancer Incidence

CHAPTER 4 BREAST CANCER SCREENING PROGRAMS

Introduction
Breast Self-Examination

Clinical Breast Examination
Mammography
Digital Breast Tomosynthesis
Ultrasonography
Magnetic Resonance Imaging (MRI)
BRCA Oncogene Mutations

CHAPTER 5 BREAST CANCER MARKET DYNAMICS

Market Drivers

Increasing Incidence of Breast Cancer Worldwide

Market Restraints

Pricing Pressure Experienced by Innovators

High Cost Associated with New Drug Development and Clinical Trials

Regulatory and Reimbursement Hurdles

Market Opportunities

Rising Female Population in Asia Pacific

Increased Demand for Technology Innovation

Technological Advancement in the Drug Sector

Emergence of Breast Cancer Predictive Tests

Patents at the Verge of Expiry

Breast Cancer Therapy: Unmet Needs

CHAPTER 6 MARKET BREAKDOWN BY TECHNOLOGY

Breast Cancer Diagnostics Market

Technologies

Mammography

Global Mammography Market

Limitations of Mammography

Breast Biopsy Device Market

Introduction

Global Breast Biopsy Device Market

Breast Cancer Predictive Diagnostics market

Introduction

Predictive Diagnostic Tests

Global Breast Cancer Companion Diagnostic Test Market

CHAPTER 7 MARKET BREAKDOWN BY DRUG CLASS

Overview
Breast Cancer Drug Classes
Breast Cancer Market
Antimetabolites
Taxanes
Aromatase Inhibitors
HER2 Inhibitor
Hormone Therapy

CHAPTER 8 MARKET BREAKDOWN BY REGION

Breast Cancer Incidence by Region
Global Market by Region
North America
Europe
Asia Pacific
Middle East and Africa (MEA)
South America

CHAPTER 9 REGULATORY SCENARIO

Regulatory Challenges
North America
U.S. Food and Drug Administration (FDA)
Europe
Asia-Pacific
Japan
China
South America
Brazil

CHAPTER 10 PATENT REVIEW/ NEW DEVELOPMENTS

Patent Review
Companion Diagnostics
Patent Expiration

CHAPTER 11 REIMBURSEMENT LANDSCAPE

Introduction
United States
Mammography Reimbursement
Biopsy Procedure Reimbursement
Breast Cancer Drug Reimbursement
Germany
Mammography Reimbursement
Biopsy Procedure Reimbursement
Breast Cancer Drugs Reimbursement
Mexico
Brazil

CHAPTER 12 PIPELINE ANALYSIS

Introduction
Pipeline by Phase
Phase III
Phase II
Phase I
Pipeline by Company
AbbVie Inc.
Array BioPharma Inc.
AstraZeneca
Belrose Pharmaceuticals
Beta Pharma
BioMarin Pharmaceuticals
CASI Pharmaceuticals Inc.
Celgene
Celldex Therapeutics
Celsion
Clovis
Eli Lilly
Novartis
Pfizer
Puma Biotechnology
Roche
Syndax Pharmaceuticals
Tesaro Inc.

CHAPTER 13 COMPETITIVE LANDSCAPE

Major Mammography Equipment Market Players

Major Breast Cancer Drug Market Players

CHAPTER 14 COMPANY PROFILES

ABBVIE INC.

ABBOTT LABORATORIES

ASTRAZENECA PLC

ATOSSA GENETICS INC.

BRISTOL-MYERS SQUIBB CO.

DAKO

ELI LILLY AND CO.

F. HOFFMANN-LA ROCHE AG

NANOSTRING TECHNOLOGIES

NOVARTIS INTERNATIONAL AG

PFIZER INC.

PUMA BIOTECHNOLOGY INC.

SANOFI S.A.

CHAPTER 15 APPENDIX: ABBREVIATIONS

List Of Tables

LIST OF TABLES

Summary Table: Global Breast Cancer Diagnostic and Drug Market, by Technology, Through 2024

Table 1: Difference between Normal and Benign Breast Cancer Cells

Table 2: New Female Breast Cancer Cases and Deaths in the United States, by Age, 2017

Table 3: Histological Types, Frequency of Occurrence and Rate of Survival

Table 4: Mucinous Carcinoma

Table 5: Steps and Genes Involved in Breast Cancer Metastasis

Table 6: Molecular Subtypes: Invasive Breast Cancer

Table 7: Local/Regional Recurrence, by Molecular Subtype

Table 8: Local/Regional Recurrence, by Molecular Subtype

Table 9: Local/Regional Recurrence, by Molecular Subtype

Table 10: Global Breast Cancer Incidence, 2016-2021

Table 11: Global Breast Cancer Incidence and Mortality, 2018

Table 12: New Breast Cancer Cases and Mortality (both Sexes), by Region, 2018

Table 13: New Breast Cancer Cases in the U.S., by Gender, Through 2024

Table 14: New Female Breast Cancer Cases and Deaths in the U.S., by Age, 2018

Table 15: Mammography Recommendations

Table 16: Femara Revenue, 2009-2015

Table 17: Generic Versions of Letrazole

Table 18: Global Mammography Market, by Region, Through 2024

Table 19: Global Mammography Market, by Device Type, Through 2024

Table 20: Global Breast Cancer Biopsy Device Market, by Region, Through 2024

Table 21: Breast Cancer Prognostics, Diagnostics, Monitoring and Grading Diagnostics Tests, 2017

Table 22: Breast Cancer Drugs

Table 23: Global Breast Cancer Drug Market, by Drug Class, Through 2024

Table 24: Global Aromatase Inhibitor Drug Market, by Drug Type, Through 2024

Table 25: Global HER2 Inhibitor Drug Market, by Drug Type, Through 2024

Table 26: Global Hormone Receptor Drug Market, by Drug Type, Through 2024

Table 27: Global Breast Cancer Therapy Market, by Region, Through 2024

Table 28: North American Breast Cancer Therapy Market, by Country, Through 2024

Table 29: European Breast Cancer Therapy Market, by Country, Through 2024

Table 30: Asia-Pacific Breast Cancer Therapy Market, by Country, Through 2024

Table 31: FDA-Approved Drugs, 1996-2019

- Table 32: List of FDA-Approved Companion Diagnostics, 2018
- Table 33: Breast Cancer Drugs Approved by the EMA, 1995-2018
- Table 34: Companion Diagnostics Patent Review, 2015-2017
- Table 35: Breast Cancer Therapeutics Patent Review, 2010-2018
- Table 36: Patent Expiration of Breast Cancer Drugs
- Table 37: Mammography Reimbursement, U.S., 2017
- Table 38: Biopsy Procedure Reimbursement, U.S., 2017
- Table 39: Medicare Part B: Breast Cancer Drugs Payment Limit, 2018
- Table 40: German Mammography In-Patient Reimbursement
- Table 41: In-Patient Biopsy Procedure Codes
- Table 42: Gemzar and Herceptin Reimbursement, Germany, 2017
- Table 43: hase III Breast Cancer Therapy Pipeline
- Table 44: Phase II Breast Cancer Therapy Pipeline
- Table 45: Phase I Breast Cancer Therapy Pipeline
- Table 46: AbbVie Inc.: Pipeline Drugs
- Table 47: Array BioPharma Inc.: Pipeline Drugs
- Table 48: AstraZeneca: Pipeline Drugs
- Table 49: Belrose Pharmaceuticals: Pipeline Drugs
- Table 50: Beta Pharma: Pipeline Drugs
- Table 51: BioMarin Pharmaceuticals: Pipeline Drugs
- Table 52: ASI Pharmaceuticals Inc.: Pipeline Drugs
- Table 53: Celgene: Pipeline Drugs
- Table 54: Celldex Therapeutics: Pipeline Drugs
- Table 55: Celsion: Pipeline Drugs
- Table 56: Clovis: Pipeline Drugs
- Table 57: Eli Lilly: Pipeline Drugs
- Table 58: Novartis: Pipeline Drugs
- Table 59: Pfizer Inc.: Pipeline Drugs
- Table 60: Puma Biotechnology: Pipeline Drugs
- Table 61: Roche: Pipeline Drugs
- Table 62: Syndax Pharmaceuticals: Pipeline Drugs
- Table 63: Tesaro Inc.: Pipeline Drugs
- Table 64: AbbVie Inc.: Company Net Revenue, 2016-2018
- Table 65: Abbott Laboratories: Company Net Revenue, 2016-2018
- Table 66: Abbott Laboratories: Marketed Products, 2018
- Table 67: AstraZeneca PLC: Company Net Revenue, 2016-2018
- Table 68: AstraZeneca PLC: Marketed Products, 2018
- Table 69: Bristol-Myers Squibb Co.: Net Revenue, 2016-2018
- Table 70: Eli Lilly and Co.: Net Revenue, 2016-2018

Table 71: F. Hoffmann-La Roche Ltd.: Net Revenue, by Segment, 2016-2018

Table 72: Novartis International AG: Net Revenue, by Segment, 2016-2018

Table 73: Pfizer Inc.: Net Revenue, 2016-2018

Table 74: Abbreviations Used in Breast Cancer Diagnostic and Drug Technology

List Of Figures

LIST OF FIGURES

Summary Figure: Global Breast Cancer Diagnostic and Drug Market, by Technology, 2018-2024

Figure 1: Breast Anatomy of Normal and Cancerous Ducts and Lobules

Figure 2: Market Shares of Invasive and Non-invasive Breast Cancer, United States, 2017

Figure 3: Histopathological Classification of Breast Cancer

Figure 4: Invasive Breast Cancer Market Share, by Type

Figure 5: Occurrence of Molecular Subtypes Share

Figure 6: Global Burden of Breast Cancer

Figure 7: National Cancer Institute Research Funding, 2011-2016

Figure 8: NCRI Breast Cancer Research Spending, 2009-2017

Figure 9: Mammography Procedures in U.S., Canada and Mexico, 2010-2015

Figure 10: Mammography Procedures in Europe, by Country, 2010-2015

Figure 11: Mammography Procedures in Asia-Pacific, by Country 2010-2015

Figure 12: Global Mammography Market, 2018-2024

Figure 13: Global Breast Cancer Drug Market Share, by Drug Class, 2018

Figure 14: Global Aromatase Inhibitor Drug Market, by Drug Type, 2018-2024

Figure 15: Global HER2 Inhibitor Drug Market, by Drug Type, 2018-2024

Figure 16: Global Hormone Receptor Drug Market, by Drug Type, 2018-2024

Figure 17: Middle East and African Breast Cancer Therapy Market, 2018-2024

Figure 18: South American Breast Cancer Therapy Market, 2018-2024

Figure 19: Federal and Inter-Provincial Approval System for Cancer Drugs in Canada

Figure 20: PMDA Medical Device Approval Procedure

Figure 21: Reimbursement of Drugs in Germany

Figure 22: Global Market Share of Mammography Equipment, by Company, 2018*

Figure 23: Global Market Share of Breast Cancer Drugs, by Company, 2018

Figure 24: AbbVie Inc.: Net Revenue, 2016-2018

Figure 25: AbbVie Inc.: Lupron Sales, 2016-2018

Figure 26: Abbott Laboratories: Revenue Share, by Segment, 2018

Figure 27: Bristol-Myers Squibb Co.: Revenue Share, by Region, 2018

Figure 28: Bristol-Myers Squibb Co.: Revenue Share, by Business Segment, 2018

Figure 29: Eli Lilly and Co.: Revenue Share, by Region, 2018

Figure 30: F. Hoffmann-La Roche Ltd.: Pharmaceutical Revenue Share, by Business Segment, 2018

Figure 31: F. Hoffmann-La Roche Ltd.: Breast Cancer Drug Revenue, 2016-2018

Figure 32: F. Hoffmann-La Roche Ltd.: Breast Cancer Drug Revenue Share, by Region, 2018

Figure 33: Sanofi S.A.: Pharmaceuticals Segment Revenue Share, by Therapy, 2018

Figure 34: Sanofi S.A.: Breast Cancer Drug Taxotere Revenue, 2011-2017

I would like to order

Product name: Breast Cancer Diagnostic and Drug Technologies: Global Markets

Product link: <https://marketpublishers.com/r/B80E6364683EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B80E6364683EN.html>